Browse the evidence

Adiponectin levels do not differ between birth weight groups in middle-aged adults, suggesting adiponectin does not mediate the link between birth weight and obesity/diabetes risk.

Unlike leptin, adiponectin levels do not appear to be influenced by birth weight in middle-aged adults. Therefore, strategies to improve metabolic health should not focus on manipulating adiponectin levels based on birth weight history.

Abdominal obesity indices (CVAI, NC, WC, WHR, LAP, VAI) are not associated with the prevalence of diabetic retinopathy (DR) in diabetic adults, regardless of BMI adjustment.

Clinicians should not rely on abdominal obesity indices (like CVAI or Neck Circumference) to screen for diabetic retinopathy risk. Regular eye exams remain the gold standard for DR detection, as these body measurements do not correlate with retinal disease prevalence in diabetic patients.

Disruption of both GLP-1 and GIP receptors (double incretin receptor knockout) induces resistance to high-fat diet-induced obesity and preserves insulin sensitivity despite impaired pancreatic beta-cell adaptation.

This research highlights that the GLP-1 and GIP pathways play a critical role in regulating body weight and energy expenditure beyond just insulin production. While this study uses genetic knockout in mice, it supports the mechanism of action for GLP-1 receptor agonists used in weight management, suggesting that these drugs work by modulating energy expenditure and adipokine secretion in addition to glucose control.

Untreated diabetic patients fail to increase adipose tissue lipoprotein lipase (LPL) activity in response to high-carbohydrate feeding due to defective insulin secretion, whereas control subjects show marked increases.

In untreated diabetes, the body's normal response to eating carbohydrates (increasing fat-storage enzymes) is broken because insulin secretion is low. This contributes to hypertriglyceridemia.

Genetic deficiency or resistance to Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) signaling extends longevity and healthspan in laboratory mice.

This research highlights a biological trade-off: reducing GH/IGF-1 signaling extends lifespan in mice but comes with a cost of smaller body size and reduced fertility. While this suggests that lower hormone levels might be protective against age-related diseases, it does not currently support GH supplementation for longevity in humans, as excess GH may actually reduce life expectancy. The focus should be on understanding the downstream metabolic benefits rather than simply maximizing hormone levels.

Calorie restriction and acute oxidative stress regulate mitochondrial adaptation through a shared mechanism involving the dynamic nuclear localization and proteasomal degradation of PGC-1α, mediated by SIRT1 and GSK3β.

Calorie restriction triggers a specific cellular repair program (mitochondrial adaptation) by regulating the PGC-1α protein. This suggests that reducing caloric intake is a signal for cellular maintenance and longevity, mediated by enzymes like SIRT1. While this paper details the molecular mechanism in mice, the practical takeaway is that moderate caloric restriction may activate these conserved survival pathways.

AMPK is not required for insulin-stimulated glucose uptake in skeletal muscle, as AMPK-deficient mouse models show normal insulin-stimulated glucose uptake.

Your body has multiple ways to manage glucose. Even if one pathway (like AMPK) is not functioning optimally, other mechanisms can still work. This highlights the importance of overall metabolic health rather than focusing on a single molecule.

Liver-specific deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) improves glucose homeostasis and lipid profiles in mice by enhancing hepatic insulin signaling and suppressing endoplasmic reticulum (ER) stress, independent of changes in body weight or adiposity.

This research suggests that improving insulin sensitivity specifically in the liver, potentially by inhibiting PTP1B, can fix metabolic issues like high blood sugar and bad cholesterol without needing to lose weight. While this is a genetic study in mice, it highlights the liver's critical role in metabolic health and suggests that future therapies might target liver-specific pathways to treat diabetes and metabolic syndrome.

Gut microbiota composition directly modulates insulin sensitivity in Toll-like receptor 2 (TLR2) knockout mice, where a specific microbial profile (increased Firmicutes, decreased Bifidobacterium) induces insulin resistance, glucose intolerance, and obesity, effectively reversing the genetically protected phenotype.

Your genetic makeup does not guarantee metabolic health. Even if you have a genetic profile that typically protects against insulin resistance, your gut microbiota can override this protection. Maintaining a healthy gut microbiome through diet and lifestyle is crucial for insulin sensitivity, regardless of your genetic background.

Restoring or altering gut microbiota composition via broad-spectrum antibiotics or microbiota transplantation can reverse insulin resistance and metabolic syndrome symptoms in TLR2 knockout mice.

Modifying your gut microbiota can significantly impact your metabolic health. In cases where genetic factors predispose you to insulin resistance, interventions that alter gut bacteria (such as specific dietary changes or, in medical contexts, antibiotics) can help restore insulin sensitivity and prevent obesity.

Increased gut permeability (leaky gut) and elevated serum LPS levels are key mechanisms by which altered gut microbiota induces insulin resistance in TLR2 knockout mice.

A healthy gut barrier is essential for metabolic health. Leaky gut allows bacterial toxins (LPS) into the bloodstream, triggering inflammation that blocks insulin action. Maintaining gut integrity through diet and lifestyle is crucial for preventing insulin resistance.

The orexigenic effects of Neuropeptide Y are mediated primarily through Y1 and Y5 receptors, with Y1 playing a dominant role in appetitive behavior and Y5 in consummatory behavior.

The brain uses specific receptors (Y1 and Y5) to process hunger signals from Neuropeptide Y. Blocking these receptors can inhibit the hunger-stimulating effects of NPY.

Genetic obesity models with leptin signaling failure (e.g., Zucker rats, ob/ob mice) exhibit increased NPY mRNA and peptide levels, whereas other genetic obesity models (e.g., agouti, tubby mice) show decreased NPY in the arcuate nucleus but increased expression in the dorsomedial nucleus.

In some genetic forms of obesity where the body cannot respond to leptin, hunger signals (NPY) are abnormally high. In other genetic forms, the hunger signal in one part of the brain (ARC) is low, but high in another (DMN), suggesting complex regulation.

Overexpression of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) protects against the development of diet-induced obesity and insulin resistance by inhibiting adipogenesis.

While this study focuses on genetic overexpression in mice, it suggests that maintaining healthy levels of IGFBP-2 may support metabolic health. Future research may explore ways to naturally boost IGFBP-2, but for now, a balanced diet and regular exercise remain the most effective strategies for managing weight and insulin sensitivity.

Rapid postnatal weight gain (catch-up growth) in infants born small for gestational age (SGA) or growth-restrained in utero significantly increases the risk of central fat deposition, insulin resistance, and adult obesity.

If your baby was born small for their gestational age, be mindful of rapid weight gain in the first two years. While catching up in height is good, excessive weight gain can lead to higher body fat and insulin resistance later in life. Focus on healthy feeding practices, such as breastfeeding and introducing solids at 6 months, rather than forcing high caloric intake.

Aging and Alzheimer's disease are associated with impaired glymphatic clearance due to the loss of AQP4 polarization and reduced arterial pulsations.

As you age, your brain's natural waste clearance system becomes less efficient due to structural changes. Prioritizing sleep quality and Omega-3 intake may help mitigate this decline and support the clearance of toxic proteins like amyloid-beta.

Roux-en-Y gastric bypass (RYGB) surgery increases circulating bile acids and TGR5 signaling, but this increase does not significantly predict changes in glucose homeostasis (insulin sensitivity/secretion) or resting energy expenditure.

If you undergo Roux-en-Y gastric bypass, your body will produce significantly more bile acids. However, this specific increase does not appear to be the main reason your blood sugar control or energy expenditure improves. The metabolic benefits of this surgery likely come from other mechanisms, not just the bile acid surge.

Low-dose melatonin (0.3 mg) administered before sleep does not improve sleep duration, quality, or structure in astronauts during spaceflight.

Low-dose melatonin (0.3 mg) is not a reliable sleep aid for astronauts in space. While it worked in lab settings, it failed to improve sleep in the operational spaceflight environment. Do not rely on it as a primary countermeasure for sleep loss in high-stress, irregular environments.

Chronic elevation of hypothalamic leptin tone, as seen in diet-induced obesity and aging, leads to central leptin resistance primarily through defects in the PI3K-PDE3B-cAMP signaling pathway rather than the JAK2-STAT3 pathway.

Obesity is not caused by a lack of leptin; in fact, obese individuals often have high levels of it. The problem is that the brain stops listening to the signal due to a specific signaling pathway defect (PI3K-PDE3B-cAMP). Therefore, simply increasing leptin (via supplements or injections) is unlikely to work for weight loss in obese individuals because the underlying resistance mechanism remains. Treatment strategies need to address the signaling defect, not just hormone levels.

Prenatal or early-life exposure to obesogenic endocrine disrupting chemicals (EDCs) such as tributyltin or rosiglitazone alters the epigenome of multipotent stromal stem cells (MSCs), biasing them toward the adipocyte lineage and resulting in a lifelong increase in adipocyte number (hypercellularity) and predisposition to obesity.

Prevention of obesity may require minimizing exposure to specific endocrine-disrupting chemicals (like certain plastics, pesticides, and pharmaceuticals) during pregnancy and early childhood, as these exposures can biologically program the body to store more fat cells for life, making weight management significantly harder later on.

Methionine restriction (0.17% dietary methionine) reduces visceral fat mass and preserves insulin sensitivity in aging male rats independently of energy restriction.

This study suggests that restricting methionine intake to 0.17% of the diet can significantly reduce visceral fat and improve insulin sensitivity in aging male rats, independent of calorie intake. While this is a robust finding in rats, direct application to humans requires further research, as human metabolism and dietary requirements differ significantly from Fischer 344 rats.

In human obesity, elevated circulating leptin levels do not result in weight loss or reduced adiposity due to central leptin resistance, primarily caused by impaired transport across the blood-brain barrier and downstream signaling defects.

Having high leptin levels does not mean your body is successfully managing your weight. In obesity, the brain stops listening to leptin signals due to transport and signaling issues. This is not a permanent genetic sentence but a reversible physiological state. Weight loss can improve leptin sensitivity, breaking the cycle of resistance.

Prenatal exposure to the organochlorine pesticide DDT and its metabolite DDE increases the risk of developing metabolic syndrome (including obesity, insulin resistance, and hypertension) in offspring, primarily through epigenetic programming of energy expenditure and hypothalamic development rather than increased caloric intake.

If you have a family history of metabolic syndrome, consider that your risk may be influenced by environmental exposures your mother encountered during pregnancy, not just your current diet. While you cannot change your prenatal history, being aware of this risk factor allows for earlier screening and more aggressive management of blood pressure and glucose levels, as your body may be predisposed to store fat and resist insulin due to early-life programming.

The protective effect of CD38 deficiency against obesity requires intact SIRT1 activity, mediated by increased NAD levels.

NAD levels are crucial for activating SIRT1, which in turn activates PGC1alpha to burn fat. CD38 breaks down NAD, so high CD38 activity might hinder weight loss. Maintaining NAD levels (through exercise or potentially supplements) may support this pathway.